Glucocorticoid (GC) therapy is one of the methods of choices for treatment of autoimmune diseases (ADs). In addition, adrenal androgens are known as immunoprotective GC-antagonists.
Introduction
IgA nephropathy (IgAN) is the most frequent primary glomerulonephritis worldwide. In this autoimmune disease, aberrantly O-glycosylated IgA1 hinge region serves as an antigen recognized by antiglycan antibodies. This stimulates a formation of nephritogenic immune complexes (Mestecky et al. 2013) , the accumulation of which in the kidney mesangium induces a proliferation of mesangial cells, expansion of extracellular matrix proteins and renal injury, leading to an end-stage renal failure in 20-40 % of patients. Progressive IgAN patients may be treated with glucocorticoids (GCs) (Lai et al. 2016 , Matousovic et al. 2015 . However, this therapy in IgAN is questionable (Lv et al. 2012 , Rauen et al. 2015 , Tesar et al. 2015 . Although GC-administration represents the most powerful therapy for rapid attenuation of inflammatory response, longtime GC-treatment is accompanied by serious complications such as disruption of hypothalamopituitary-adrenal (HPA) axis and inhibition of gonadal activity (Mastorakos et al. 2006, Rengarajan and Balasubramanian 2008) . As adrenal androgens are GC-antagonists, we evaluated their levels in groups of healthy controls (H), GC-untreated (U) and GC-treated S434 Šterzl et al. Vol. 66 (T) patients with other autoimmune diseases (ADs), and in IgAN patients before prednisolone treatment (N0), and after one week (N1) and one month (N2) of prednisolone therapy. Since natural 7α/β-and 16α-hydroxy-steroids are immunomodulatory, anti-inflammatory and immunoprotective (Ahlem et al. 2011a , Ahlem et al. 2011b , Auci et al. 2009 , Conrad et al. 2010 , Hennebert et al. 2007 , Le Mee et al. 2008 , Loria 2002 , Pettersson et al. 2010 , Reading et al. 2012 , Tang et al. 2006 we focused on these substances.
Methods

Subjects
The study enrolled 23 women and 43 men. The study groups consisted of healthy controls (H, n=10), untreated controls without IgAN but suffering from other ADs (U, n=10), GC treated non-IgAN controls suffering from other ADs (T, n=9), and patients with IgAN (n=14) who were monitored before prednisolone treatment (N0), after one week (N1) and one month (N2) of prednisolone therapy. The U-group enrolled patients with idiopathic membranous glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, glomerulopathy, and suspenzia chronic mesangioproliferative glomerulonephritis. The T-group consisted of patients with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic impairment of connective tissues, polymyalgia rheumatica and giant cell arteritis, membranous nephropathy, complete nephrotic syndrome and glomerular and segmental glomerulosclerosis. Prednisolone dose was 60 mg of prednisolone/day/m 2 of body surface. The patients have been recruited from the Nephrological Outpatient Department (NOPD) of the Motol University Hospital and from the neighboring NOPDs in Prague and NOPD of Palacký University Olomouc. No samples from the female subjects were collected in the luteal menstrual phase. The mean age of the participants was 48.4± 15.1 years (mean ± SD) and the age differences between the study groups were insignificant.
The Ethics Committee of the Institute of Endocrinology in Prague approved the protocol of the study, and written informed consent was obtained from all participants.
Analytical methods
The circulating levels of steroids and their polar conjugates were measured using a previously described gas chromatographic-mass spectrometric method (Hill et al. 2010) .
Statistical analysis
The between-group differences were evaluated using one-way ANOVA. Changes in steroid levels were assessed using repeated measures ANOVA. The ANOVA testing was followed by Duncan's multiple comparisons (Duncan 1955) . The original data were transformed by power transformations to attain Gaussian data distribution and constant variance. Statgraphics Centurion, version XV statistical software from Manugistics, (Herndon, MA, USA) was used for the calculations.
Results
Steroid levels
Most steroids showed significant between-group differences (Table 1) and there was a trend of decreasing in steroid levels during the prednisolone therapy (Table 2) . Estradiol was higher in the IgAN patients irrespectively of GC-treatment.
Shifted balance between adrenal C21 and C19-Δ 5steroids towards the C21 steroids in IgAN patients
Dehydroepiandrosterone (DHEA) to pregnenolone ratio ( Fig. 1A) was higher in the H-group than in the other groups while the dehydroepiandrosterone sulfate (DHEAS) to pregnenolone sulfate ratio did not significantly differ between the H and N0-groups ( Fig. 1B ). Both ratios (reflecting CYP17A1lyase step) decreased during the GC-treatment of IgAN patients. The values and statistics for repeated measures ANOVA in the DHEA/pregnenolone ratio were F=26.51, p<0.001: N0=5.66 (4.72, 6.73 -mean with 95 % confidence limits), N1=2.7 (2.14, 3.36), N2=2.06 (1.57, 2.64), N0-N1, N0-N2 (significant differences between stages N0 and N1 and between stages N0 and N2). For the DHEAS/pregnenolone sulfate ratio they were F=4.02, p=0.031: N0=15.2 (12.3, 18.6), N1=11.9 (9.69, 14.5), N2=10.1 (8.22, 12.4 ), N0-N2.
Increased conversion of DHEA to androstenedione reflecting type 2 3β-hydroxysteroid dehydrogenase (HSD3B2) activity in IgAN patients
Androstenedione/DHEA ( Fig. 1C ) and androstenedione/DHEAS ( Fig. 1D ) ratios reflecting type 2 3β-hydroxysteroid dehydrogenase (HSD3B2) activity were higher in the GC-treated groups. The values 
The differences were evaluated by one-way ANOVA after Box-Cox transformations of original data for attainment of Gaussian distribution and constant variance. The ANOVA testing was followed by Duncan's multiple comparisons. F and p represent F-statistics and their p-values, respectively. The steroid levels are shown as retransformed means with their 95 % confidence intervals.
F represents Fisher's statistics in ANOVA testing and p symbolizes its significance level. The symbols separated by hyphen represent significant between-group differences (p<0.05). and statistics for repeated measures ANOVA for the androstenedione/DHEA ratio were F=7.23, p=0.003: N0=0.561 (0.422, 0.738), N1=0.983 (0.755, 1.27), N2=1.07 (0.824, 1.38), N0-N1, N0-N2. For the androstenedione/DHEAS ratio they were F=17.61, p<0.001: N0=0.0028 (0.0021, 0.0037), N1=0.0066 (0.0052, 0.0081), N2=0.0067 (0.0054, 0.0081), N0-N1, N0-N2. The values in the H-groups were lower in comparison with the other groups for the androstenedione/DHEA ratio and similar results were found for the androstenedione/DHEAS ratio except for insignificant difference between the H and N0-groups. Figure 2A shows the product to precursor ratio based on the levels of 7α-hydroxy-DHEA (DHEA7α), 5-androstene-3β,7α,17β-triol (AT7α), DHEA and androstenediol. This (DHEA7α+AT7α)/(DHEA+ androstenediol) ratio exemplifies a conversion of DHEA and androstenediol to their 7α-hydroxy-metabolites. This ratio was elevated in IgAN groups and showed an increase at the second stage of GC-therapy of IgAN patients (F=5.14, p=0.014: N0=0.101 (0.085, 0.122), N1=0.094 (0.079, 0.114), N2=0.139 (0.115, 0.173), N0-N2, N1-N2). Figure 2B shows the product to precursor ratio based on the levels of 7β-hydroxy-DHEA (DHEA7β), 5-androstene-3β, 7β,17β-triol (AT7β), DHEA and androstenediol. This (DHEA7β+AT7β)/(DHEA+ androstenediol) ratio illustrating a conversion of DHEA and androstenediol to their immunomodulatory 7β-hydroxy-metabolites exhibited a similar picture as in the case of 7α-hydroxylation, except the transient increase during the GC-treatment (F=2.99, p=0.068: N0=0.079 (0.061, 0.105), N1=0.124 (0.0914, 0.176), N2=0.117 (0.087, 0.164), N0-N1).
Changing 7α-, 7β-and 16α-hydroxylation of Δ 5 -steroids in IgAN patients during the prednisolone treatment
The 16α-hydroxypregnenolone/pregnenolone ratio reflecting the 16α-hydroxylation of pregnenolone was also elevated in IgAN patients (Fig. 2C) . However, Significant  differences:  H-T, H-N0, U-N0,  U-N1, T-N0, T-N1,  T-N2, N0-N2   A B C CYP3A4,7 CYP7B1 CYP3A4,7 this ratio decreased after GC-application (F=7.82, p=0.002: N0=0.479 (0.393, 0.583), N1=0.366 (0.3, 0.447), N2=0.279 (0.228, 0.34), N0-N2).
16α-Hydroxypregnenolone/pregnenolone Group
Discussion
Reduced activity of adrenal zona reticularis (ZR) in IgAN patients DHEA is an endogenous antiglucocorticoid serving as a precursor for the synthesis of 30-50 % of androgens in men and 100 % of estrogens in postmenopausal women (Labrie et al. 1998) . At physiological concentrations, this steroid stimulates the interleukin 2 (IL-2) secretion from T helper cells type 1 (Th1) cells but suppresses tumor necrosis factor α (TNFα) and interleukin β (IL1β) production and activation of nuclear transcription factor κB (NF-κB) pathway. DHEA mediates a cytotoxicity induced by T lymphocytes and enhances the natural killer (NK) cell cytotoxicity by stimulation of insulin-like growth factor 1 (IGF-1) production in NK cells. Furthermore, DHEA suppresses type 1 11β-hydroxysteroid dehydrogenase (HSD11B1) mRNA in adipose tissue and promotes the mRNA expression of type 2 11β-hydroxysteroid dehydrogenase (HSD11B2) in renal cells. HSD11B1 metabolite androstenediol, but not the DHEA, protects from viral-induced mortality (Loria 2002). In DHEA, DHEAS, androstenediol and DHEA/pregnenolone ratio, the between-group differences in adrenal androgens showed higher levels in the H-group in comparison with the N0-group, which indicates primarily reduced activity of the adrenal zona reticularis (ZR) in IgAN patients.
Glucocorticoid therapy additionally suppresses adrenal steroidogenesis in IgAN patients including the production of androgens and their immunoprotective 7-and 16αoxygenated metabolites
The suppression of the hormonal production in zona fasciculata (ZF) by prednisolone therapy was more prominent than the one in ZR as the DHEA/pregnenolone and DHEAS/pregnenolone ratios descended during the prednisolone treatment of IgAN patients. Endogenous GCs but not their synthetic analogues rapidly and dosedependently stimulated DHEA secretion. Cortisol had no influence on steroid C17-hydroxylase-C17,20-lyase (CYP17A1) but suppressed the activity HSD3B2 activity (Topor et al. 2011) . The lack of natural GCs in IgAN patients elevated HSD3B2 activity, which promoted the conversion of adrenal C19-Δ 5 -steroids to their Δ 4 -counterparts and consequently reduced the levels of substrates for the synthesis of immunoprotective C19-Δ 5 -7α/β-and 16α-hydroxy-steroids, the synthesis of which is catalyzed by cytochrome P450 7B1 (CYP7B1), HSD11B1, cytochrome P450 3A4 (CYP3A4) and cytochrome P450 3A7 (CYP3A7). Significant or borderline decrease during the GC-treatment was obvious in all C19-Δ 5 -steroids.
Increased estradiol levels in IgAN patients irrespectively of GC-therapy and amplified conversion of DHEA to androstenedione in IgAN patients
Adrenal androgens may be peripherally converted to autoimmunity-inducing estradiol (Ahlem et al. 2011a , Ahlem et al. 2011b , Auci et al. 2009 , Conrad et al. 2010 , Hennebert et al. 2007 , Le Mee et al. 2008 , Loria 2002 , Pettersson et al. 2010 , Reading et al. 2012 , Tang et al. 2006 . However, in spite of reduced synthesis of C19-Δ 5 -steroids in IgAN patients we surprisingly found higher estradiol levels (independently of GC therapy) when compared with non-IgAN groups (Tables 1 and 2) . The estrogen overproduction in IgAN patients may be associated with an amplified conversion of DHEA to androstenedione (catalyzed by HSD3B2) as was observed in these subjects because the androstenedione is a key estrogen precursor (Luu-The 2013). Androstenedione/DHEA and androstenedione/ DHEAS ratios mounted during the GC-therapy and were higher in the T-group when compared with the H-group. We also found a different androstenedione/DHEAS ratio in the U-group when compared with both the H-group (higher values) and the T-group (lower values). Therefore, higher estradiol levels in IgAN groups may be also associated with increased aromatase activity.
Alterations in 7α-, 7β-, and 16α-hydroxylation of Δ 5 -steroids
The mechanism explaining the immunomodulatory effects of 7α/β-Δ 5 -steroids may be associated with a competition of 7-oxygenated androstanes for the active sites on the HSD11B1, which catalyzes the conversion of inactive 11-oxo-glucocorticoids to their immunosuppressive 11β-hydroxy-counterparts (Hennebert et al. 2007 , Le Mee et al. 2008 .
Whereas estradiol induces autoimmunity via estrogen receptors, another mechanism is linked to the catabolism of C19 estrogen precursors such as DHEA, androstenediol, and 5α-androstane-3β,17β-diol (that are S440 Šterzl et al.
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also estrogenic) to their 7-oxygenated and 16α-hydroxylated catabolites, which cannot be further converted to bioactive estrogens (Pettersson et al. 2010) . Androstenediol, even at low concentrations is active on both types of estrogen receptors. The AT7β, which may be either formed by interconversion from the AT7α or directly from androstenediol by the catalytic action of CYP3A4 and CYP3A7, is immunoprotective in spite of its low concentration and high clearance (Ahlem et al. 2011b ). The synthetic antiinflammatory derivatives of AT7β suppress the production of C-reactive protein interleukin 17 (IL-17), TNFα, interleukin 6 (IL-6) signaling and expression of mRNAs for IL-6 and matrix metalloproteinase in inflamed tissue but intensely stimulate the splenic regulatory T cells and suppress pro-inflammatory cytokines in the lungs (Reading et al. 2012) . Estradiol may stimulate the catalytic CYP7B1 activity, mRNA, and human CYP7B1 reporter gene in human embryonic kidney cells HEK293 and may control the DHEA, estradiol, and androstenediol levels in human tissues (Tang et al. 2006) . We have demonstrated that DHEA7β, but not DHEA and DHEA7α reduces the immunosuppressive effect of GCs on the formation of plaques in murine spleen lymphocytes (Sterzl et al. 1999) . Therefore, the elevated conversion of the C19-Δ 5 -steroids to their 7α-and 7β-hydroxy-metabolites (catalyzed by CYP7B1, CYP3A4, CY3A7 and HSD11B1) in IgAN patients may represent a counterregulatory mechanism compensating the lack of C19-Δ 5 deoxysteroids by amplified synthesis of their more efficient 7-oxygenated (autoimmunity-suppressing) metabolites. The 16α-hydroxylation of pregnenolone (catalyzed by CYP3A4, CYP3A7, CYP7B1) is also higher in IgAN patients. The only difference is the suppression of 16α-hydroxypregnenolone/pregnenolone ratio by GCs.
Possibilities of therapeutic co-application of Δ 5 -steroids and glucocorticoids
The C19-Δ 5 -steroids mitigate the severity of ADs (Bottasso et al. 2007 , Du et al. 2001 , Choi et al. 2008 , Rontzsch et al. 2004 , Sudo et al. 2001 , Tan et al. 2009 ) but ADs may weaken the production of adrenal C19-Δ 5 -steroids (Bottasso et al. 2007 , Kasperska-Zajac et al. 2008 . DHEA controls the Th1/Th2 balance and either shifts it towards the Th1 component or attenuates the production of both components (Choi et al. 2008 , Romagnani et al. 1998 . The C19-Δ 5 -steroids also suppress cell-mediated immunity and formation of autoantibodies (Choi et al. 2008 , Pratschke et al. 2014 , Rontzsch et al. 2004 , Sudo et al. 2001 , Tan et al. 2009 ). Hence, the co-application of immunosuppressive corticoids with immunoprotective Δ 5 -steroids inducing restoration of the Th1-dominated cytokine profile (Hernandez-Pando et al. 1998b ) may be favorable for the treatment of ADs. The GC-treatment alone exhibits more than 55 % risk for adverse events (Lv et al. 2012 ) and the therapy exclusively with Δ 5 -steroids may be unsafe as well (Hernandez-Pando et al. 1998b) . The therapeutic efficiency of androstenediol is higher in comparison with DHEA and the application of adrenal androgens is optimal in an early phase of Th1-mediated response and before the switch to the Th2-mediated stage (Hernandez-Pando et al. 1998a ).
